XSHE
002198
Market cap248mUSD
Jul 10, Last price
3.43CNY
1D
3.31%
1Q
-56.19%
Jan 2017
-74.55%
IPO
-4.90%
Name
Guangdong Jiaying Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guangdong Jiaying Pharmaceutical Co., Ltd. is engaged in the comprehensive process of researching, developing, manufacturing, and marketing traditional Chinese medicines. Its operations span a vast international territory, encompassing Mainland China, Taiwan, Hong Kong, Macao, Southeast Asia, Europe, and the United States. The company primarily offers therapeutic solutions for a variety of health issues, such as throat conditions, common colds, orthopedic ailments, rheumatic diseases, gynecological disorders, conditions requiring heat-clearing, and gastrointestinal problems. These medical preparations are provided in numerous formats, including powders, tablets, capsules, granules, and pills. The distribution of its product line occurs through both independent agencies and direct sales points. The firm's operational hub is situated in Meizhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||